Figure 2From: Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapyTime course of measured median absolute neutrophil count in cycle 1 (intent-to-treat population). ANC absolute neutrophil count.Back to article page